Merck to Acquire Caraway Therapeutics, Inc.
Caraway Therapeutics to Present at 22nd Annual Needham Healthcare Conference
Caraway Therapeutics to Present at Stifel CNS Days
Caraway Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Caraway, a digital healthcare company for Gen Z, announces its partnership with Ash Wellness, an at-home diagnostics and testing company, to combat the rise in sexually transmitted infections (STIs) on college campuses. Caraway's members can now access complimentary, discrete and on-demand STI kits delivered directly to their addresses in New York, California, Ohio and North Carolina, with follow-up guidance and treatment by an integrated care team. The partnership provides Gen Z with the tools they need to prioritize their sexual health on their own terms.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be participating in two upcoming investor conferences.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be presenting new data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference, taking place October 13, 2022, in New York, New York. Magdalene Moran, Ph.D., President & Chief Scientific Officer of Caraway and Donato del Camino, Ph. D., Vice President of Drug Discovery will present the poster “Advancing TRPML1 Agonists for GBA-PD”, detailing the Company’s TRPML1 program currently in preclinical development for GBA-Parkinson’s disease (GBA-PD).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be participating in the William Blair Biotech Focus Conference, taking place July 13, 2022, in New York City. Caraway’s Chief Executive Officer, Martin D. Williams, will participate in a fireside chat with Myles Minter, PhD, Biotech Equity Research Analyst at William Blair, to discuss recent advances in the Company’s lead program targeting the lysosomal cation channel, TRPML1, for the treatment of GBA-Parkinson’s disease (GBA-PD) and other rare genetic diseases.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be presenting at the Stifel CNS Days event on Tuesday, March 29, 2022, at 3:00pm Eastern Time. Caraway’s Chief Executive Officer, Martin D. Williams, will highlight recent advances in the company’s lead program targeting the lysosomal cation channel, TRPML1, for the treatment of GBA-Parkinson’s disease (GBA-PD) and other rare genetic diseases.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be presenting at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 9:20am Eastern Time. Caraway’s Chief Executive Officer, Martin D. Williams, will highlight recent advances in the company’s lead program targeting the lysosomal cation channel, TRPML1, for the treatment of GBA-Parkinson’s disease and other rare genetic diseases.